Creative Planning reduced its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 2.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 652 shares of the medical instruments supplier’s stock after selling 13 shares during the period. Creative Planning’s holdings in ICU Medical were worth $112,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GW&K Investment Management LLC boosted its stake in shares of ICU Medical by 2.7% in the second quarter. GW&K Investment Management LLC now owns 495,697 shares of the medical instruments supplier’s stock valued at $85,508,000 after buying an additional 12,808 shares during the period. Goldman Sachs Group Inc. increased its position in shares of ICU Medical by 17.1% in the first quarter. Goldman Sachs Group Inc. now owns 374,203 shares of the medical instruments supplier’s stock valued at $57,141,000 after buying an additional 54,756 shares in the last quarter. Janus Capital Management LLC increased its position in shares of ICU Medical by 178.8% in the first quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock valued at $219,864,000 after buying an additional 923,395 shares in the last quarter. Lyon Street Capital LLC purchased a new position in shares of ICU Medical during the first quarter valued at approximately $3,022,000. Finally, Jane Street Group LLC purchased a new position in shares of ICU Medical during the first quarter valued at approximately $431,000. Institutional investors and hedge funds own 77.10% of the company’s stock.

Shares of ICU Medical, Inc. (NASDAQ:ICUI) traded up 0.41% on Wednesday, reaching $169.60. 25,780 shares of the company’s stock traded hands. ICU Medical, Inc. has a one year low of $120.14 and a one year high of $176.50. The company’s 50-day moving average price is $171.87 and its 200 day moving average price is $159.53. The firm has a market cap of $3.36 billion, a P/E ratio of 67.92 and a beta of 0.37.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by $0.06. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The firm had revenue of $331.51 million during the quarter, compared to the consensus estimate of $318.30 million. During the same period in the previous year, the business earned $1.15 earnings per share. The firm’s revenue for the quarter was up 242.8% on a year-over-year basis. On average, equities analysts forecast that ICU Medical, Inc. will post $4.11 EPS for the current fiscal year.

WARNING: “Creative Planning Sells 13 Shares of ICU Medical, Inc. (ICUI)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/creative-planning-sells-13-shares-of-icu-medical-inc-icui/1495966.html.

Several research analysts have commented on ICUI shares. Zacks Investment Research downgraded shares of ICU Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 3rd. Sidoti downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 20th. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Roth Capital downgraded shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Thursday, May 11th. They noted that the move was a valuation call. Finally, Gabelli restated a “buy” rating on shares of ICU Medical in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $193.00.

In other ICU Medical news, CEO Vivek Jain sold 69,014 shares of the firm’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $171.10, for a total value of $11,808,295.40. Following the completion of the transaction, the chief executive officer now directly owns 110,925 shares of the company’s stock, valued at approximately $18,979,267.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott E. Lamb sold 23,772 shares of the firm’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $170.02, for a total transaction of $4,041,715.44. Following the completion of the transaction, the chief financial officer now directly owns 9,050 shares of the company’s stock, valued at $1,538,681. The disclosure for this sale can be found here. Over the last three months, insiders sold 203,965 shares of company stock valued at $34,856,920. Insiders own 15.90% of the company’s stock.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.